T2	Intervention 742 849	The patients were assigned to 5 groups: placebo, 200 mg, 400 mg, 600 mg and 800 mg of ebrotidine once daily
T1	Intervention 851 958	Controls were performed at baseline and every two weeks at four follow-up visits unless ulcer healed before
T3	Intervention 1071 1138	Vital signs and blood/ urine analysis were used to establish safety
